COVID-19疫苗试验中定期无症状检测的实施与依从性
COV002是一项评估ChAdOx1 nCoV-19疫苗的2/3期试验,采用每周自采样拭子RT-PCR检测无症状感染。10,811名参与者13个月随访期间自采样356,551次,中位依从性75.0%,依从性随周下降,老年、女性及非医护人员更高。试验表明长期定期无症状检测策略可行。
要点
- 10,811名参与者13个月自采样356,551次,中位依从性75.0%(IQR 42.6-90.9)。
- 依从性对应检测到无症状感染的概率为74.5%(IQR 50.9-78.8)。
- 每周返还拭子的几率下降8%,阳性及揭盲后进一步下降。
核心结论
- COV002试验证明长期定期无症状检测策略具有可行性,可为未来以感染为结局的III期疫苗试验设计提供参考。
研究设计与样本
- COV002是一项评估ChAdOx1 nCoV-19疫苗抗SARS-CoV-2的2/3期试验,采用每周自采样拭子RT-PCR检测无症状感染,使用混合效应回归模型分析依从性。
- 共10,811名参与者,13个月随访期间自采样356,551次。
主要发现
- 中位依从性为75.0%(IQR 42.6-90.9),对应检测到阳性无症状感染的概率为74.5%(IQR 50.9-78.8)。
- 疫苗效力评价期间出现21至96例假阳性。
- 每周返还拭子的几率下降8%,检测阳性及揭盲后进一步下降。
- 依从性在较年长年龄组、女性及非医护人员中更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For pathogens which cause infections that present asymptomatically, evaluating vaccine efficacy (VE) against asymptomatic infection is important for understanding a vaccine's potential epidemiological impact. Regular testing for subclinical infections is a potentially valuable strategy but its success hinges on participant adherence and minimising false positives. This paper describes the implementation and adherence to weekly testing in a COVID-19 vaccine trial. METHODS: COV002 was a phase 2/3 trial assessing the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Asymptomatic infections were detected using weekly self-administered swabs for RT-PCR testing. We analysed adherence using mixed-effects regression models and estimated the probability of true and false positive asymptomatic infections using estimates of adherence and testing characteristics. FINDINGS: 356,551 tests were self-administered by 10,811 participants during the 13-month follow-up. Median adherence was 75.0% (IQR 42·6-90·9), which translated to a 74·5% (IQR 50·9-78·8) probability of detecting a positive asymptomatic infection during the swabbing period, and between 21 and 96 false positives during VE evaluation. The odds of returning a swab declined by 8% per week and further after testing positive and unblinding. Adherence was higher in older age groups, females and non-healthcare workers. INTERPRETATION: The COV002 trial demonstrated the feasibility of running a long-term regular asymptomatic testing strategy. This information could be valuable for designing future phase III vaccine trials in which infection is an outcome. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, AstraZeneca.
引用
- Williams LR, Emary KRW, Phillips DJ, et al. Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial. Vaccine. 2024. PMID: 39060202. doi:10.1016/j.vaccine.2024.126167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。